Press Releases

Press Releases

 
Press Releases
Date Title and Summary View
Jul 21, 2016 SAN DIEGO, July 21, 2016 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, will release its second quarter 2016 financial results after the market closes on Tuesday, August 2, 2016 followed by a ...
May 23, 2016 SAN DIEGO, May 23, 2016 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced the first subject was recently enrolled in its phase 3 trial designated VTL-308.  There are now ten ...
May 9, 2016 SAN DIEGO, May 09, 2016 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced results for the first quarter ended March 31, 2016. ...
Apr 28, 2016 SAN DIEGO, April 28, 2016 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, will release its first quarter 2016 financial results after the market closes on Monday, May 9, 2016. The press release will be followed by a confe...
Mar 8, 2016 SAN DIEGO, March 08, 2016 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced results for the fourth quarter and full year ended December 31, 2015 and provided a corporate update. "Since the FDA's re...
Feb 24, 2016 SAN DIEGO, Feb. 24, 2016 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of liver failure, will release its fourth quarter and full year 2015 financial results after the market closes on Tuesday, March 8, 2016. The press release ...
Nov 19, 2015 SAN DIEGO, Nov. 19, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of liver failure, announced that it has received written responses from the FDA to its Type C meeting request on the planned VTL-308 phase 3 clinical trial. At the FDA's su...
Nov 18, 2015 SAN DIEGO, Nov. 18, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of liver failure, announced two presentations were given this week at The Liver Meeting, the annual meeting of the American Association for the Study of Liver Disease (AASLD), ...
Nov 5, 2015 SAN DIEGO, Nov. 5, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of liver failure, today announced results for the third quarter ended September 30, 2015 and provided a corporate update. "Since we announced in late August that our VTI-208...
Oct 28, 2015 SAN DIEGO, Oct. 28, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing the ELAD® System, a cell-based therapy targeting the treatment of liver failure, today announced the closing of its previously announced underwritten public offering of 6,272,727 shares of its common stock at a price to the publ...
Page: FirstPrevious
2
... NextLast
= add release to Briefcase